Wall Street brokerages expect that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will report earnings per share of ($0.58) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Dova Pharmaceuticals’ earnings, with estimates ranging from ($0.68) to ($0.52). Dova Pharmaceuticals reported earnings per share of ($0.32) in the same quarter last year, which would suggest a negative year over year growth rate of 81.3%. The company is expected to report its next earnings report on Thursday, August 9th.
On average, analysts expect that Dova Pharmaceuticals will report full-year earnings of ($2.18) per share for the current financial year, with EPS estimates ranging from ($2.79) to ($1.93). For the next year, analysts anticipate that the company will post earnings of ($0.57) per share, with EPS estimates ranging from ($1.24) to $0.50. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.05).
In related news, major shareholder Life Sciences Maste Perceptive purchased 10,000 shares of the stock in a transaction that occurred on Monday, June 4th. The shares were purchased at an average price of $25.07 per share, with a total value of $250,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul B. Manning purchased 120,000 shares of the stock in a transaction that occurred on Tuesday, June 5th. The shares were bought at an average cost of $26.17 per share, for a total transaction of $3,140,400.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 301,700 shares of company stock worth $8,319,082. Corporate insiders own 55.50% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company grew its holdings in shares of Dova Pharmaceuticals by 702.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock worth $137,000 after buying an additional 4,163 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Dova Pharmaceuticals by 148.6% during the first quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock worth $145,000 after buying an additional 3,195 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Dova Pharmaceuticals during the first quarter worth about $220,000. Virtus Fund Advisers LLC purchased a new position in shares of Dova Pharmaceuticals during the fourth quarter worth about $318,000. Finally, Deutsche Bank AG grew its holdings in shares of Dova Pharmaceuticals by 139.2% during the fourth quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock worth $337,000 after buying an additional 6,836 shares during the last quarter. 35.93% of the stock is currently owned by hedge funds and other institutional investors.
Shares of DOVA stock opened at $30.35 on Friday. The company has a market cap of $854.48 million and a P/E ratio of -21.68. Dova Pharmaceuticals has a 52-week low of $16.98 and a 52-week high of $37.00.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.